Essentials of Atrial Fibrillation

This handbook offers timely investigation of current pharmaceutical trends, clinical guidelines, novel treatments, and ongoing pipeline developments, including ground-breaking advances in the use of novel oral anticoagulants. Atrial fibrillation (AF) affects an estimated 1–2% of the population and i...

Full description

Bibliographic Details
Main Authors: Yap, Yee Guan, Camm, A John (Author)
Format: eBook
Language:English
Published: Tarporley Springer Healthcare Ltd. 2014, 2014
Edition:1st ed. 2014
Subjects:
Online Access:
Collection: Springer eBooks 2005- - Collection details see MPG.ReNa
LEADER 01990nmm a2200385 u 4500
001 EB000897132
003 EBX01000000000000000694252
005 00000000000000.0
007 cr|||||||||||||||||||||
008 141008 ||| eng
020 |a 9781907673986 
100 1 |a Yap, Yee Guan 
245 0 0 |a Essentials of Atrial Fibrillation  |h Elektronische Ressource  |c by Yee Guan Yap, A John Camm 
250 |a 1st ed. 2014 
260 |a Tarporley  |b Springer Healthcare Ltd.  |c 2014, 2014 
300 |a VIII, 47 p. 11 illus., 4 illus. in color  |b online resource 
505 0 |a Epidemiology of atrial fibrillation -- Pathogenesis of atrial fibrillation -- Classification, diagnosis, and assessment of atrial fibrillation -- Rate and rhythm control strategies for atrial fibrillation -- Anticoagulant treatment strategies for atrial fibrillation 
653 |a Primary Care Medicine 
653 |a Pharmacotherapy 
653 |a Hematology 
653 |a Public health 
653 |a Internal medicine 
653 |a Cardiology 
653 |a Hematology 
653 |a Cardiology 
653 |a Pharmacotherapy 
653 |a Internal Medicine 
653 |a Primary care (Medicine) 
653 |a Public Health 
700 1 |a Camm, A John  |e [author] 
041 0 7 |a eng  |2 ISO 639-2 
989 |b Springer  |a Springer eBooks 2005- 
856 4 0 |u https://doi.org/10.1007/978-1-907673-98-6?nosfx=y  |x Verlag  |3 Volltext 
082 0 |a 616 
520 |a This handbook offers timely investigation of current pharmaceutical trends, clinical guidelines, novel treatments, and ongoing pipeline developments, including ground-breaking advances in the use of novel oral anticoagulants. Atrial fibrillation (AF) affects an estimated 1–2% of the population and is the most common cause of sustained cardiac arrhythmia. Critically, the number of patients developing AF is expected to double in the next five decades, leading to increased incidence of stroke, heart failure and other serious thromboembolic events